ReviewJournal of cancer research and clinical oncology2015
The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells.
Review in Journal of cancer research and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- High Glucose Alters Extracellular Vesicle Protein Composition and Promotes EV-Mediated Monocyte Adhesion to Endothelial Cells.International journal of molecular sciences · 2026Article
- A miR-383-5p Signaling Hub Coordinates the Axon Regeneration Response to Inflammation.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- How mitochondrial dynamics imbalance affects the progression of breast cancer:a mini review.Medical oncology (Northwood, London, England) · 2024Review
- Peroxiredoxin 3 Inhibits Cardiac Fibrosis in Mice via NOX4-P38 Signalling.Cell journal · 2023Article
- Grass Carp Prx 3 Elevates Host Antioxidant Activity and Induces Autophagy to Inhibit Grass Carp Reovirus (GCRV) Replication.Antioxidants (Basel, Switzerland) · 2022Article
- Dissecting Regulators of Aging and Age-Related Macular Degeneration in the Retinal Pigment Epithelium.Oxidative medicine and cellular longevity · 2022Article
- Targeting Mitochondrial Oncometabolites: A New Approach to Overcome Drug Resistance in Cancer.Pharmaceutics · 2021Review
- Modulation of Mitochondrial Metabolic Reprogramming and Oxidative Stress to Overcome Chemoresistance in Cancer.Biomolecules · 2020Review
- Interplay Between Mitochondrial Peroxiredoxins and ROS in Cancer Development and Progression.International journal of molecular sciences · 2019Review
- The Role of Peroxiredoxin Family in Cancer Signaling.Journal of cancer prevention · 2019Review
- Transforming Growth Factor-β Drives the Transendothelial Migration of Hepatocellular Carcinoma Cells.International journal of molecular sciences · 2017Article
- The role of peroxiredoxins in cancer.Molecular and clinical oncology · 2017Article
- Mitochondrial peroxiredoxins are essential in regulating the relationship between Drosophila immunity and aging.Biochimica et biophysica acta. Molecular basis of disease · 2017Article
- New Challenges to Study Heterogeneity in Cancer Redox Metabolism.Frontiers in cell and developmental biology · 2017Review
- Peroxiredoxin-3 Is Involved in Bactericidal Activity through the Regulation of Mitochondrial Reactive Oxygen Species.Immune network · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe mammalian peroxiredoxin (PRX) family contains six members that provide antioxidant defense in different cell types by removing reactive oxygen species (ROS) through conserved active cysteines. Different from other members, PRX3 is predominantly located in mitochondria, a major apoptosis mediator. The purpose of this review is to summarize the findings on PRX3 concerning its role in ROS removal, apoptosis, and chemoresistance of cancer cells.
methodsThe relevant literature from PubMed and Medline databases is reviewed in this article (1994-2014).
resultsBecause of fast growth and relatively low supply of oxygen in cancer cells, ROS production from mitochondria is exaggerated to an extent that overwhelms cellular antioxidant defenses resulting in oxidative stress. As an active responder to oxidative stress, PRX3 is accordingly up-regulated in cancer cells to remove cellular ROS and inhibit apoptosis, which provides a favorable microenvironment for cell proliferation.
conclusionSince most of chemotherapy or radiotherapy for cancers is through ROS increase and apoptotic induction, PRX3 might be involved in the chemotherapeutic resistance of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.